Labels: sources manual selection automatic selection
Ann Clin Transl Neurol. 2021 Feb 24. doi: 10.1002/acn3.51324. Online ahead of print.
OBJECTIVE: No relapse risk prediction tool is currently available to guide treatment selection for multiple sclerosis (MS). Leveraging …
Mol Immunol. 2021 Feb 20;133:23-33. doi: 10.1016/j.molimm.2021.02.008. Online ahead of print.
Multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) are neuroinflammatory autoimmune …
Clin Optom (Auckl). 2021 Feb 12;13:39-49. doi: 10.2147/OPTO.S286862. eCollection 2021.
PURPOSE: Oculomotor disorders have been reported in multiple sclerosis (MS) in up to 80% of cases. There have been studies evaluating …
Current strategies for the treatment of demyelinating diseases such as multiple sclerosis (MS) are based on anti-inflammatory or immunomodulatory drugs. Those drugs have the potential to reduce the frequency of new lesions but do …
Articles listed here come from the following sites, with keyword searches for
Multiple Sclerosis, autoimmune encephalomyelitis, encephalomyelitis, immune tolerance, myelin.